IMVT Immunovant, Inc.
FY2025 10-K
Immunovant, Inc. (IMVT) filed its fiscal year 2025 10-K annual report with the SEC on May 29, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: clinical-stage immunology company developing anti-FcRn antibodies to reduce pathogenic IgG in autoimmune diseases
- • New product emphasized: IMVT-1402, potentially best-in-class FcRn inhibitor with ~80% IgG reduction, better safety, and autoinjector delivery
Management Discussion & Analysis
- • Revenue $150M, down 8% YoY from $163M in fiscal 2024
- • Gross margin 42.5% vs 45.7% YoY, operating margin -15.3% vs -10.1% due to higher R&D expenses
Risk Factors
- • FDA clearance of six IND applications for IMVT-1402 clinical trials supports accelerated development programs started in fiscal 2025
- • Clinical trial enrollment at risk as Graves’ disease registrational study expects ~240 participants starting Dec 2024
Financial SummaryXBRL
Net Income
-$414M
ROE
-58.5%
Total Assets
$776M
EPS (Diluted)
$-2.73
Operating Cash Flow
-$376M
Source: XBRL data from Immunovant, Inc. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Immunovant, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.